Castle Biosciences (CSTL) Short term Debt (2019 - 2026)

Castle Biosciences has reported Short term Debt for 6 years, with the latest figure at $2.9 million in Q2 2026.

• Quarterly Short term Debt rose 50.05% year-over-year to $2.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.9 million (up 50.05% YoY) and the FY2025 annual result came in at $417000.0, up 50.0% from the prior year.
• Short term Debt improved to $2.9 million in Q2 2026 per CSTL's latest filing, from $1.7 million in the prior quarter.
• Over five years, Short term Debt peaked at $20.8 million in Q1 2022 and troughed at $278000.0 in Q4 2024.
• A 4-year average of $4.2 million and a median of $1.7 million in 2026 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2025 and 2026: Short term Debt soared 50.0% in 2025, then jumped 50.05% in 2026.
• Over 4 years, Short term Debt stood at $20.8 million in 2022, then slumped by 98.67% to $278000.0 in 2024, then jumped by 50.0% to $417000.0 in 2025, then soared by 599.52% to $2.9 million in 2026.
• According to Business Quant data, Short term Debt over the past three periods registered $2.9 million, $1.7 million, and $417000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.